Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Single-Blind, Active-Control, Parallel Group Study to Evaluate Safety and Activity of a Single Administration of F14 for Management of Postoperative Pain in Participants Undergoing Unilateral Total Knee Replacement

Next Previous
Trial Profile

A Phase 2, Randomized, Single-Blind, Active-Control, Parallel Group Study to Evaluate Safety and Activity of a Single Administration of F14 for Management of Postoperative Pain in Participants Undergoing Unilateral Total Knee Replacement

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Bupivacaine
  • Indications Inflammation; Postoperative pain
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Arthritis Innovation Corporation

Most Recent Events

  • 04 Jun 2020 Status changed from active, no longer recruiting to completed, according to a MedinCell S.A media release.
  • 13 Jan 2020 According to a MedinCell S.A. media release, 20 participants have completed their 3-month follow-up visit last summer. Trial completion is expected in March 2020.
  • 25 Sep 2019 According to a MedinCell S.A. media release, the compnay announced this study is progressing well and on schedule. The analysis of the data is being completed by the company's partner and its subcontracted clinical research organization.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top